- call +1-201-465-4211
- email sales@mrinsights.biz
Scope of the Report:
The global Selective Cox-2 Inhibitors market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Selective Cox-2 Inhibitors.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Selective Cox-2 Inhibitors market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Selective Cox-2 Inhibitors market by product type and applications/end industries.
Market Segment by Companies, this report covers
Boehringer-Ingelheim
TerSera Therapeutics
Iroko Pharmaceuticals
Apotex
Yung Shin Pharmaceutical
Breckenridge Pharmaceutical
Meda Pharmaceuticals
Cipla
Glenmark Pharmaceuticals
Teva
PuraCap Pharmaceutical
Almirall Limited
Lupin Pharmaceuticals
Aurobindo Pharma
Pfizer
Mylan
Shire Pharmaceuticals
Bayer
Novacap
Abbott
Geri-Care
Perrigo
Kopran
Merck
Hengrui pharmaceutical
Kelun Group
Qilu Pharmaceutical
Taro Pharmaceuticals
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Meloxicam
Celecoxib
Etoricoxib
Imrecoxib
Etodolac
Parecoxib
Other
Market Segment by Applications, can be divided into
Rheumatoid Arthritis
Osteoarthritis
Spondylosis Chronica Ankylopoietica
Other
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Selective Cox-2 Inhibitors Market Overview
1.1 Product Overview and Scope of Selective Cox-2 Inhibitors
1.2 Classification of Selective Cox-2 Inhibitors by Types
1.2.1 Global Selective Cox-2 Inhibitors Revenue Comparison by Types (2019-2024)
1.2.2 Global Selective Cox-2 Inhibitors Revenue Market Share by Types in 2018
1.2.3 Meloxicam
1.2.4 Celecoxib
1.2.5 Etoricoxib
1.2.6 Imrecoxib
1.2.7 Etodolac
1.2.8 Parecoxib
1.2.9 Other
1.3 Global Selective Cox-2 Inhibitors Market by Application
1.3.1 Global Selective Cox-2 Inhibitors Market Size and Market Share Comparison by Applications (2014-2024)
1.3.2 Rheumatoid Arthritis
1.3.3 Osteoarthritis
1.3.4 Spondylosis Chronica Ankylopoietica
1.3.5 Other
1.4 Global Selective Cox-2 Inhibitors Market by Regions
1.4.1 Global Selective Cox-2 Inhibitors Market Size (Million USD) Comparison by Regions (2014-2024)
1.4.1 North America (USA, Canada and Mexico) Selective Cox-2 Inhibitors Status and Prospect (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Selective Cox-2 Inhibitors Status and Prospect (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Selective Cox-2 Inhibitors Status and Prospect (2014-2024)
1.4.4 South America (Brazil, Argentina, Colombia) Selective Cox-2 Inhibitors Status and Prospect (2014-2024)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Selective Cox-2 Inhibitors Status and Prospect (2014-2024)
1.5 Global Market Size of Selective Cox-2 Inhibitors (2014-2024)
2 Manufacturers Profiles
2.1 Boehringer-Ingelheim
2.1.1 Business Overview
2.1.2 Selective Cox-2 Inhibitors Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Boehringer-Ingelheim Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.2 TerSera Therapeutics
2.2.1 Business Overview
2.2.2 Selective Cox-2 Inhibitors Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 TerSera Therapeutics Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.3 Iroko Pharmaceuticals
2.3.1 Business Overview
2.3.2 Selective Cox-2 Inhibitors Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.4 Apotex
2.4.1 Business Overview
2.4.2 Selective Cox-2 Inhibitors Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Apotex Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.5 Yung Shin Pharmaceutical
2.5.1 Business Overview
2.5.2 Selective Cox-2 Inhibitors Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.6 Breckenridge Pharmaceutical
2.6.1 Business Overview
2.6.2 Selective Cox-2 Inhibitors Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.7 Meda Pharmaceuticals
2.7.1 Business Overview
2.7.2 Selective Cox-2 Inhibitors Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Meda Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.8 Cipla
2.8.1 Business Overview
2.8.2 Selective Cox-2 Inhibitors Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Cipla Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.9 Glenmark Pharmaceuticals
2.9.1 Business Overview
2.9.2 Selective Cox-2 Inhibitors Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.10 Teva
2.10.1 Business Overview
2.10.2 Selective Cox-2 Inhibitors Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Teva Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.11 PuraCap Pharmaceutical
2.11.1 Business Overview
2.11.2 Selective Cox-2 Inhibitors Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.12 Almirall Limited
2.12.1 Business Overview
2.12.2 Selective Cox-2 Inhibitors Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Almirall Limited Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.13 Lupin Pharmaceuticals
2.13.1 Business Overview
2.13.2 Selective Cox-2 Inhibitors Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.14 Aurobindo Pharma
2.14.1 Business Overview
2.14.2 Selective Cox-2 Inhibitors Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Aurobindo Pharma Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.15 Pfizer
2.15.1 Business Overview
2.15.2 Selective Cox-2 Inhibitors Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Pfizer Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.16 Mylan
2.16.1 Business Overview
2.16.2 Selective Cox-2 Inhibitors Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Mylan Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.17 Shire Pharmaceuticals
2.17.1 Business Overview
2.17.2 Selective Cox-2 Inhibitors Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 Shire Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.18 Bayer
2.18.1 Business Overview
2.18.2 Selective Cox-2 Inhibitors Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 Bayer Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.19 Novacap
2.19.1 Business Overview
2.19.2 Selective Cox-2 Inhibitors Type and Applications
2.19.2.1 Product A
2.19.2.2 Product B
2.19.3 Novacap Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.20 Abbott
2.20.1 Business Overview
2.20.2 Selective Cox-2 Inhibitors Type and Applications
2.20.2.1 Product A
2.20.2.2 Product B
2.20.3 Abbott Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.21 Geri-Care
2.21.1 Business Overview
2.2.2 Selective Cox-2 Inhibitors Type and Applications
2.21.2.1 Product A
2.21.2.2 Product B
2.21.3 Geri-Care Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.22 Perrigo
2.22.1 Business Overview
2.22.2 Selective Cox-2 Inhibitors Type and Applications
2.22.2.1 Product A
2.22.2.2 Product B
2.22.3 Perrigo Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.23 Kopran
2.23.1 Business Overview
2.23.2 Selective Cox-2 Inhibitors Type and Applications
2.23.2.1 Product A
2.23.2.2 Product B
2.23.3 Kopran Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.24 Merck
2.24.1 Business Overview
2.24.2 Selective Cox-2 Inhibitors Type and Applications
2.24.2.1 Product A
2.24.2.2 Product B
2.24.3 Merck Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.25 Hengrui pharmaceutical
2.25.1 Business Overview
2.25.2 Selective Cox-2 Inhibitors Type and Applications
2.25.2.1 Product A
2.25.2.2 Product B
2.25.3 Hengrui pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.26 Kelun Group
2.26.1 Business Overview
2.26.2 Selective Cox-2 Inhibitors Type and Applications
2.26.2.1 Product A
2.26.2.2 Product B
2.26.3 Kelun Group Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.27 Qilu Pharmaceutical
2.27.1 Business Overview
2.27.2 Selective Cox-2 Inhibitors Type and Applications
2.27.2.1 Product A
2.27.2.2 Product B
2.27.3 Qilu Pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
2.28 Taro Pharmaceuticals
2.28.1 Business Overview
2.28.2 Selective Cox-2 Inhibitors Type and Applications
2.28.2.1 Product A
2.28.2.2 Product B
2.28.3 Taro Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
3 Global Selective Cox-2 Inhibitors Market Competition, by Players
3.1 Global Selective Cox-2 Inhibitors Revenue and Share by Players (2014-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 Selective Cox-2 Inhibitors Players Market Share
3.2.2 Top 10 Selective Cox-2 Inhibitors Players Market Share
3.3 Market Competition Trend
4 Global Selective Cox-2 Inhibitors Market Size by Regions
4.1 Global Selective Cox-2 Inhibitors Revenue and Market Share by Regions
4.2 North America Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
4.3 Europe Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
4.4 Asia-Pacific Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
4.5 South America Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
4.6 Middle East and Africa Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
5 North America Selective Cox-2 Inhibitors Revenue by Countries
5.1 North America Selective Cox-2 Inhibitors Revenue by Countries (2014-2019)
5.2 USA Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
5.3 Canada Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
5.4 Mexico Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
6 Europe Selective Cox-2 Inhibitors Revenue by Countries
6.1 Europe Selective Cox-2 Inhibitors Revenue by Countries (2014-2019)
6.2 Germany Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
6.3 UK Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
6.4 France Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
6.5 Russia Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
6.6 Italy Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
7 Asia-Pacific Selective Cox-2 Inhibitors Revenue by Countries
7.1 Asia-Pacific Selective Cox-2 Inhibitors Revenue by Countries (2014-2019)
7.2 China Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
7.3 Japan Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
7.4 Korea Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
7.5 India Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
7.6 Southeast Asia Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
8 South America Selective Cox-2 Inhibitors Revenue by Countries
8.1 South America Selective Cox-2 Inhibitors Revenue by Countries (2014-2019)
8.2 Brazil Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
8.3 Argentina Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
8.4 Colombia Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
9 Middle East and Africa Revenue Selective Cox-2 Inhibitors by Countries
9.1 Middle East and Africa Selective Cox-2 Inhibitors Revenue by Countries (2014-2019)
9.2 Saudi Arabia Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
9.3 UAE Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
9.4 Egypt Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
9.5 Nigeria Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
9.6 South Africa Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
10 Global Selective Cox-2 Inhibitors Market Segment by Type
10.1 Global Selective Cox-2 Inhibitors Revenue and Market Share by Type (2014-2019)
10.2 Global Selective Cox-2 Inhibitors Market Forecast by Type (2019-2024)
10.3 Meloxicam Revenue Growth Rate (2014-2024)
10.4 Celecoxib Revenue Growth Rate (2014-2024)
10.5 Etoricoxib Revenue Growth Rate (2014-2024)
10.6 Imrecoxib Revenue Growth Rate (2014-2024)
10.7 Etodolac Revenue Growth Rate (2014-2024)
10.8 Parecoxib Revenue Growth Rate (2014-2024)
10.9 Other Revenue Growth Rate (2014-2024)
11 Global Selective Cox-2 Inhibitors Market Segment by Application
11.1 Global Selective Cox-2 Inhibitors Revenue Market Share by Application (2014-2019)
11.2 Selective Cox-2 Inhibitors Market Forecast by Application (2019-2024)
11.3 Rheumatoid Arthritis Revenue Growth (2014-2019)
11.4 Osteoarthritis Revenue Growth (2014-2019)
11.5 Spondylosis Chronica Ankylopoietica Revenue Growth (2014-2019)
11.6 Other Revenue Growth (2014-2019)
12 Global Selective Cox-2 Inhibitors Market Size Forecast (2019-2024)
12.1 Global Selective Cox-2 Inhibitors Market Size Forecast (2019-2024)
12.2 Global Selective Cox-2 Inhibitors Market Forecast by Regions (2019-2024)
12.3 North America Selective Cox-2 Inhibitors Revenue Market Forecast (2019-2024)
12.4 Europe Selective Cox-2 Inhibitors Revenue Market Forecast (2019-2024)
12.5 Asia-Pacific Selective Cox-2 Inhibitors Revenue Market Forecast (2019-2024)
12.6 South America Selective Cox-2 Inhibitors Revenue Market Forecast (2019-2024)
12.7 Middle East and Africa Selective Cox-2 Inhibitors Revenue Market Forecast (2019-2024)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Selective Cox-2 Inhibitors Picture
Table Product Specifications of Selective Cox-2 Inhibitors
Table Global Selective Cox-2 Inhibitors and Revenue (Million USD) Marke
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
